You are here: Industry Insights > Astellas

News List

Astellas’ non-hormonal VMS therapy gets FDA approval SHEM OIRERE
June 08, 2023
U.S. Food and Drug Administration has approved Veozah, the first neurokinin 3 receptor antagonist, to treat moderate to severe vasomotor symptoms.
Astellas Pharma and Dyno Therapeutics Sign Option and License Agreement contractpharma
December 03, 2021
Will collaborate to develop next-gen AAV gene therapy vectors for skeletal and cardiac muscle.
Astellas and Dyno Therapeutics to develop AAV gene therapy vectors Pharmaceutical-Technology
December 03, 2021
Astellas Pharma has signed an option and licence agreement with Dyno Therapeutics to develop next-generation adeno-associated virus (AAV) gene therapy vectors for skeletal and cardiac muscle.
Astellas and Pantherna Enter into Technology Evaluation Agreement for Research of mRNA-based Regenerative Medicine FirstWordPharma
November 15, 2021
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pantherna Therapeutics GmbH (CEO: Klaus Giese, Ph.D., "Pantherna") today announced that the companies...
Astellas and Minovia Therapeutics to Collaborate on New Mitochondrial Cell Therapies americanpharmaceuticalreview
August 02, 2021
Minovia Therapeutics, Ltd. and Astellas Pharma Inc. announced a worldwide strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction.
FDA Expands Indication for PROGRAF® for Lung Transplant Recipients americanpharmaceuticalreview
July 22, 2021
Astellas Pharma Inc. announced that the U.S. FDA approved its supplemental New Drug Application (sNDA) for PROGRAF® (tacrolimus) for the prevention of organ rejection in adult and pediatric lung transplant recipients.
Affinivax, Astellas’ pneumococcal vaccine wins breakthrough therapy status pharmatimes
July 16, 2021
Affinivax and Astellas’ pneumococcal vaccine candidate ASP3772 has been granted a breakthrough therapy designation by the US Food and Drug Administration (FDA), the companies announced earlier this week.
U.S. FDA Grants Regular Approval and Expands Indication for Padcev (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer drugs
July 16, 2021
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) granted Padcev (enfortumab vedotin-ejfv) regular approval in the U.S.
Astellas’ Xtandi bags NICE approval in prostate cancer pharmatimes
June 10, 2021
Astellas’ oral treatment Xtandi has received approval from the National Institute for Health and Care Excellence (NICE) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC).
Cross-industry alliance launches to increase awareness of cell and gene therapies in the UK pharmatimes
May 19, 2021
A new cross-industry alliance between leading pharma and biotech companies has launched in a bid to raise awareness and boost understanding of cell and gene therapies in the UK.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page